Ovid Therapeutics (NASDAQ:OVID) outlined new pipeline and financing updates alongside its fourth-quarter and full-year 2025 ...

This article discusses whether now is the right time to buy Treasuries for your portfolio.

Organizational restructuring and cost reduction plan following results of the Phase 3 CYPRESS study of ampreloxetine are underway; expected to generate ...

BDC equity is sold on the stock market, just like closed end funds. Also like closed end funds, BDCs routinely post their Net ...

Rising geopolitical tensions, particularly the US-Iran conflict, have driven up oil prices and inflation expectations. Read ...

Joining me today are Dr. Thomas Errico, one of our founders and investor and Chairman of the electroCore Board of Directors; ...

Following recent inflation adjustments, federal estate, gift, and generation-skipping transfer (GST) tax exemptions have soared to a record-high ...

The next generation of mobile networks is expected to be rolled out in a few years. But what exactly is 6G -- and how will it affect users?

Oklo Inc. (NYSE:OKLO) Q4 2025 Earnings Call Transcript March 17, 2026 Oklo Inc. misses on earnings expectations. Reported EPS is $-0.28319 EPS, expectations were $-0.16971. Operator: Gentlemen, thank ...

Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its fourth quarter and year ended ...

We reached an important milestone in Q4 ahead of our prior expectations. During the quarter, a second customer adopted our AI-driven solution for manufacturing process development known as FTCO. This ...

Silvaco Group, Inc. Common Stock (NASDAQ:SVCO) Q4 2025 Earnings Call Transcript March 12, 2026 Silvaco Group, Inc. Common Stock beats earnings expectations. Reported EPS is $-0.03, expectations were $ ...